培美替尼(培米替尼)治疗肝内胆管癌效果怎么样？

For patients with FGFR2-positive cholangiocarcinoma, the approval of Pemazyre(pemigatinib)/pemetinib is a crucial milestone. This is the first new treatment option available to these patients in the EU in more than a decade and has shown high rates of durable response in a setting where historically there has been no effective standard of care. Incyte executive director Hervé Hoppenot said: "We now look forward to working with various European countries to ensure that eligible patients have access to this new treatment as quickly as possible."

How effective is pemetinib in the treatment of intrahepatic cholangiocarcinoma? According to data from a study, the intrahepatic cholangiocarcinoma-targeted drug pemigatinib can achieve an objective response rate of 35.5% and a disease control rate of 82% in the treatment of patients with cholangiocarcinoma. The median duration of response was 9.1 months, with as many as 63% of patients having a response duration of ≥6 months and 18% of patients with a duration of ≥12 months.

It is not difficult to see from these data that the targeted drug pemigatinib has a very significant effect on disease control and improvement of prognosis of intrahepatic cholangiocarcinoma. The advent of the targeted drug pemetinib/pemigatinib (pemigatinib) is good news for many patients with intrahepatic cholangiocarcinoma. This drug has changed the current treatment status of intrahepatic cholangiocarcinoma and provided doctors and patients with a new diagnosis and treatment option.

Pemetinib/pemetinib is marketed by Incyte in the United States, Europe and Japan. Incyte has granted Innovent Biologics, Inc. the rights to develop and commercialize PemazyreB (pemigatinib) in hematology and oncology in Mainland China, Hong Kong, Macau and Taiwan. It is believed that it can bring good news to domestic patients in the near future.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.